Back to Search
Start Over
Development and Validation of Valganciclovir and its Active Metabolite Ganciclovir Determination in Human Plasma by HPLC-UV Method
- Source :
- Разработка и регистрация лекарственных средств, Vol 9, Iss 2, Pp 133-139 (2020)
- Publication Year :
- 2020
- Publisher :
- Center of Pharmaceutical Analytics Ltd, 2020.
-
Abstract
- Introduction. Viral infections are a serious problem that occurs during the use of immunosuppressants in preparation for organ transplantation and in the postoperative period. Cytomegalovirus (CMV) infection is one of the main causes of diseases in people with weakened immune systems. It has a direct impact on one’s body and makes it more likely to reject a transplanted organ. Antiviral drugs are used to treat and prevent this infectious disease. Valganciclovir is a prodrug whose active metabolite is ganciclovir. Valganciclovir is the drug of choice in the treatment of CMV infections. Currently, there are no researches on the matter of simultaneous determination of both valganciclovir and ganciclovir in human blood plasma by means of high-performance liquid chromatography (HPLC) with ultraviolet detection. This research delivers a thorough description of development and validation of a particular method for simultaneous determination of valganciclovir and ganciclovir in the plasma after sample preparation by the method of protein precipitation.Aim. The aim of this study is to develop method for the quantitative determination of valganciclovir and its active metabolite ganciclovir in human plasma by HPLC-UV for pharmacokinetic studies.Materials and methods. Quantitative determination of tadalafil in plasma by HPLC-UV. A sample was prepared using protein precipitation.Results and discussion. This method was validated by next validation parameters: selectivity, matrix effect, calibration curve, accuracy, precision, lower limit of quantification, carry-over and stability.Conclusion. The method of the quantitative determination of valganciclovir and its active metabolite ganciclovir in human plasma was developed and validated by HPLC-UV. The analytical range of the was 5,0–1000,0 ng/ml for valganciclovir and 100,0–10000,0 ng/ml for ganciclovir in plasma. Method could be applied to determination of valganciclovir and ganciclovir in plasma for PK and BE studies.
- Subjects :
- Ganciclovir
Drug
030213 general clinical medicine
ganciclovir
media_common.quotation_subject
valganciclovir
Pharmaceutical Science
030204 cardiovascular system & hematology
Pharmacology
Bioequivalence
03 medical and health sciences
0302 clinical medicine
Pharmacokinetics
Drug Discovery
medicine
Protein precipitation
plasma
hplc-uv
Pharmaceutical industry
Active metabolite
media_common
validation
bioequivalence
business.industry
Valganciclovir
Prodrug
quantitative determination
HD9665-9675
business
medicine.drug
Subjects
Details
- ISSN :
- 26585049 and 23052066
- Volume :
- 9
- Database :
- OpenAIRE
- Journal :
- Drug development & registration
- Accession number :
- edsair.doi.dedup.....54b20593e5523b99b163b7b659048673
- Full Text :
- https://doi.org/10.33380/2305-2066-2020-9-2-133-139